Company news
Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) news
Cyclerion Therapeutics, Inc. news releases on 6ix. Latest, Aug 26, 2026: Cycurion, Inc. Announces Reverse Stock Split Effective August 28, 2026
Press releases & updates
Cycurion, Inc. Announces Reverse Stock Split Effective August 28, 2026
August 26, 2026
Cycurion Confirms August 20 Nasdaq Hearing Date; Common Stock Continues Trading on Nasdaq
August 7, 2026
Cycurion Announces a Warrant Inducement Transaction for $4.5 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules
July 31, 2026
Cycurion Receives Nasdaq Delisting Determination Letter; Appeal Underway, Trading to Continue, Focus on Shareholder Value
July 16, 2026
Cyclerion Therapeutics and Korsana Biosciences Announce Merger Agreement
March 31, 2026
Cyclerion Therapeutics Announces Progress Toward CYC-126 Phase 2 Proof-of-Concept Study with FDA Feedback and Formation of Clinical Advisory Board
February 17, 2026
Cyclerion Therapeutics Announces Strategic Agreement with Medsteer and Progress Toward Initiating Phase 2 Proof-of-Concept Study for CYC-126 in Treatment-Resistant Depression
January 5, 2026
Cyclerion Announces Transformational Relaunch as a Neuropsychiatric Company
September 23, 2025
Regina Graul, Ph.D., Promoted to Chief Executive Officer
August 6, 2024
Cyclerion Appoints Regina Graul, Ph.D., as President
December 3, 2023
Cyclerion Strengthens Board of Directors with Experienced Company Builder and Cutting-edge Innovator
November 29, 2023
Cyclerion Regains Compliance with Nasdaq Minimum Bid Price Requirement
May 31, 2023
Cyclerion Announces Reverse Stock Split
May 14, 2023
Cyclerion Announces Definitive Agreement for Zagociguat and CY3018
May 10, 2023
Cyclerion Announces Corporate Updates and Q1 2023 Financial Results
May 10, 2023
Cyclerion Therapeutics Enters into Exclusive Negotiation Period and Binding Equity Investment Agreement
April 2, 2023
Cyclerion Therapeutics Receives U.S. FDA Orphan Drug Designation for Zagociguat for the Treatment of Mitochondrial Diseases
March 26, 2023
Cyclerion Reports Corporate Update and Full Year 2022 Financial Results
March 21, 2023
Cyclerion Concludes Unsolicited Proposal Is Not in The Best Interest of The Company
November 21, 2022
Cyclerion Announces Mitochondrial Disease-Focused Corporate Strategy
October 5, 2022
Cyclerion Announces CY6463 Clinical Pipeline Progress and Second Quarter 2022 Financial Results
August 8, 2022
Cyclerion Therapeutics Announces Positive Topline Clinical Data for CY6463 in Patients with Cognitive Impairment Associated with Schizophrenia (CIAS)
July 27, 2022
Steven E. Hyman, M.D., Appointed to Cyclerion Therapeutics’ Board of Directors
July 25, 2022
Cyclerion Therapeutics Announces CY6463 Data Demonstrating Improved Cellular Energetics in Preclinical Models of Mitochondrial Disease
June 16, 2022
Cyclerion Therapeutics Announces Positive Topline Clinical Data for CY6463 in MELAS Patients at UMDF Mitochondrial Medicine 2022 Symposium
June 9, 2022
Cyclerion Announces CY6463 Clinical Pipeline Progress and First Quarter 2022 Financial Results
May 3, 2022
Cyclerion Announces CY6463 Clinical Pipeline and Corporate Updates
February 23, 2022
Cyclerion Therapeutics Announces Initiation of Patient Dosing in CY6463 Phase 2a Study in Alzheimer’s Disease with Vascular Pathology
January 25, 2022
Cyclerion Therapeutics Reports Third Quarter 2021 Financial Results and Corporate Update
November 8, 2021
Cyclerion Announces Publication of Preclinical Data Demonstrating Reduction in Neuroinflammation by Brain-Penetrant sGC Stimulator
September 21, 2021
Cyclerion Therapeutics Reports Second Quarter 2021 Financial Results and Corporate Update
July 28, 2021
Cyclerion Therapeutics to Present Clinical Trial Design for CY6463 Phase 2a Study in Participants with Alzheimer’s Disease with Vascular Pathology at the Alzheimer’s Association International Conference 2021 (AAIC)
July 21, 2021
Cyclerion Therapeutics and Beacon Biosignals Announce Expanded Strategic Partnership
July 7, 2021
Cyclerion Therapeutics Announces Global Licensing Agreement with Akebia Therapeutics for Praliciguat
June 3, 2021
Cyclerion Therapeutics Announces $18 Million Private Placement
June 3, 2021
Cyclerion Therapeutics Announces Publication of CY6463 Preclinical Data in Frontiers in Pharmacology
May 26, 2021
Cyclerion Therapeutics Appoints Errol De Souza, Ph.D., to Board of Directors
April 25, 2021
Cyclerion Therapeutics Announces Departure of Chief Medical Officer
March 17, 2021
Cyclerion Therapeutics Reports Full Year 2020 Financial Results and Corporate Update
February 24, 2021
Cyclerion Therapeutics Announces Clinical and Scientific Advisory Boards
January 24, 2021
Cyclerion Announces Leadership Transitions
December 20, 2020
Cyclerion Therapeutics Reports Third Quarter 2020 Financial Results and Recent Corporate Updates
November 4, 2020
Cyclerion Announces Positive Data from IW-6463 CNS Translational Pharmacology Study in Healthy Elderly Subjects
October 13, 2020
Cyclerion Announces Phase 2 STRONG-SCD Study Results in Patients with Sickle Cell Disease
October 13, 2020
Cyclerion Announces Translational Research Award from the Alzheimer’s Association Part the Cloud-Gates Partnership Grant Program
August 24, 2020
Cyclerion Therapeutics Reports Second Quarter 2020 Financial Results and Recent Corporate Highlights
August 2, 2020
Cyclerion Therapeutics Completes $24 Million Private Placement
July 29, 2020
Cyclerion Updates Corporate Progress
April 9, 2020
Cyclerion announces IW-6463 phase 1 healthy volunteer study results that support further development for neurodegenerative diseases
January 12, 2020
Cyclerion Therapeutics Announces Topline Phase 2 Results for sGC Stimulator Praliciguat in Heart Failure with Preserved Ejection Fraction (HFpEF)
October 29, 2019